Comment
. 2004 Jun 2;96(11):883; author reply 884-5.
doi: 10.1093/jnci/djh170.
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
- PMID: 15173275
- DOI: 10.1093/jnci/djh170
Item in Clipboard
Comment
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
J Natl Cancer Inst.
.
No abstract available
Comment on
-
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64. doi: 10.1093/jnci/djg108. J Natl Cancer Inst. 2003. PMID: 14652237 Clinical Trial.
Similar articles
-
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.J Natl Cancer Inst. 2004 Jun 2;96(11):883-4; author reply 884-5. doi: 10.1093/jnci/djh159. J Natl Cancer Inst. 2004. PMID: 15173274 No abstract available.
-
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.J Natl Cancer Inst. 2004 Jun 2;96(11):884; author reply 884-5. doi: 10.1093/jnci/djh160. J Natl Cancer Inst. 2004. PMID: 15173277 No abstract available.
-
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64. doi: 10.1093/jnci/djg108. J Natl Cancer Inst. 2003. PMID: 14652237 Clinical Trial.
-
A hot flash on tamoxifen metabolism.J Natl Cancer Inst. 2003 Dec 3;95(23):1734-5. doi: 10.1093/jnci/djg129. J Natl Cancer Inst. 2003. PMID: 14652227 Review. No abstract available.
-
[New antidepressive agents].Union Med Can. 1995 Nov;124(3):8-13. Union Med Can. 1995. PMID: 8560639 Review. French. No abstract available.
Cited by
-
Prevalence of the co-prescription of tamoxifen and CYP2D6 inhibitors in Saudi population: A cross sectional study.Saudi Pharm J. 2020 Apr;28(4):440-444. doi: 10.1016/j.jsps.2020.02.004. Epub 2020 Feb 17. Saudi Pharm J. 2020. PMID: 32273802 Free PMC article.
-
Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22. J Clin Oncol. 2013. PMID: 23091108 Free PMC article. No abstract available.
-
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.Br J Cancer. 2008 Aug 19;99(4):616-21. doi: 10.1038/sj.bjc.6604533. Epub 2008 Jul 29. Br J Cancer. 2008. PMID: 18665165 Free PMC article.
-
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.Acta Oncol. 2010 Apr;49(3):305-12. doi: 10.3109/02841860903575273. Acta Oncol. 2010. PMID: 20156115 Free PMC article.
-
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.J Natl Cancer Inst. 2011 Mar 16;103(6):489-500. doi: 10.1093/jnci/djr010. Epub 2011 Feb 15. J Natl Cancer Inst. 2011. PMID: 21325141 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
